Amgen Ends Crohn's Disease Collaboration, Eliminating Over $500M in Milestone Potential
TCRX sits 16% above its 52-week low of $0.716 on light trading volume (0.3× avg).
Summary
Amgen terminated its Crohn's disease collaboration with TScan, eliminating over $500 million in potential milestone payments and royalties. The termination is effective November 10, 2026, with no penalty to TScan.
Key Events · M&A and Partnerships · TCRX
-
Amgen Terminates Collaboration
Amgen elected to terminate the Research Collaboration and License Agreement dated May 8, 2023, effective November 10, 2026, with no early termination penalty.
-
Loss of Milestone and Royalty Upside
TScan loses access to over $500 million in success-based milestone payments and tiered single-digit royalties on net sales, though the $30 million upfront payment is retained.
-
Wind-Down Obligations
TScan must use commercially reasonable efforts to wind down its activities under the current research plan promptly and efficiently.
-
Survival of Obligations
If Amgen or its affiliates continue to exploit product candidates, applicable milestone and royalty obligations will survive in accordance with the agreement.
Analysis · TCRX · Life Sciences
Amgen is walking away from the 2023 Crohn's disease research collaboration, effective November 10, 2026. TScan loses access to over $500 million in potential milestone payments and future royalties, though it keeps the $30 million upfront payment already received. This removes a major non-dilutive funding source at a time when the company has warned it may not survive as a going concern and needs to raise capital soon.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 36.9% of the 961 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TCRX was trading at $0.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $55.9M. The 52-week trading range was $0.72 to $2.57. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.